BioCryst Pharmaceuticals (BCRX) vs Maze Therapeutics (MAZE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioCryst Pharmaceuticals (BCRX) has outperformed Maze Therapeutics (MAZE) over the past year, gaining 3.6% versus a loss of 13.5%. BioCryst Pharmaceuticals is the larger company by market cap ($1.86 billion vs $1.72 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | MAZE |
|---|---|---|
| Share price | $7.22 | $31.37 |
| Market cap | $1.86B | $1.72B |
| 1-day change | -1.37% | -3.27% |
| YTD return | -7.44% | -24.28% |
| 1-year return | +3.59% | -13.49% |
| 5-year return | -42.15% | — |
| Forward P/E | 8.44 | — |
| EPS (TTM) | $-1.28 | $-2.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.84M | — |
| Revenue growth (YoY) | +94.10% | — |
| Net income (latest FY) | $263.86M | $-131.12M |
| Gross margin | 97.82% | — |
| Operating margin | 38.98% | — |
| Net margin | 30.16% | — |
| 52-week high | $11.22 | $53.65 |
| 52-week low | $6.23 | $21.95 |
| Distance from 52-week high | -35.65% | -41.53% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +183.24% | +99.11% |
| Average volume | 4.97M | 737.14K |
| Shares outstanding | 257.30M | 54.68M |
| Employees | 435 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCRX has outperformed MAZE by 17.1 percentage points over the past year.
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
BCRX vs MAZE FAQ
Which is bigger, BioCryst Pharmaceuticals or Maze Therapeutics?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $1.86B compared with $1.72B for Maze Therapeutics (MAZE).
Which stock has performed better over the past year, BCRX or MAZE?
BCRX returned +3.59% over the past 12 months, compared with -13.49% for MAZE (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Maze Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.